Showing results (191-200 of 212) with videos related to
Sort By:
Pageof 22
AIDS Research and Therapy|March 14, 2023
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravirFrank Mulindwa, Barbara Castelnuovo, Nele Brusselaers, et al.The Journal of Antimicrobial Chemotherapy|November 27, 2018
Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with SwitzerlandNadine Bachmann, Amrei von Braun, Niklaus D Labhardt, et al.Plos One|April 14, 2016
Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income CountriesM Katherine Charles, Mary Lou Lindegren, C William Wester, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 19, 2025
Adverse drug reactions related to isoniazid preventive therapy among persons living with HIV on dolutegravir-based regimens in Uganda between July 2019 and March 2020Esther Alice Nalugga, Joseph Musaazi, Yukari C Manabe, et al.BMC Medical Ethics|March 2, 2026
Strengthening research regulatory capacity in the East African community: a multi-country training program on emerging and complex study designsMathius Amperiize, Belinda Twesigye, Beth Mutumba, et al.The Lancet. HIV|April 23, 2022
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trialNicholas I Paton, Joseph Musaazi, Cissy Kityo, et al.Medrxiv : the Preprint Server for Health Sciences|June 10, 2024
Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study ProtocolChristine Sekaggya-Wiltshire, Irene Mbabazi, Ruth Nabisere-Arinaitwe, et al.Oncology|March 14, 2015
Task Shifting and Skin Punch for the Histologic Diagnosis of Kaposi's Sarcoma in Sub-Saharan Africa: A Public Health Solution to a Public Health ProblemMiriam O Laker-Oketta, Megan Wenger, Aggrey Semeere, et al.Cancer Medicine|January 30, 2016
A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcomaAggrey Semeere, Megan Wenger, Naftali Busakhala, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 19, 2007
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapyMoses R Kamya, Harriet Mayanja-Kizza, Andrew Kambugu, et al.Pageof 22